AKR1C3 polyclonal, anti-human

Protein Family: Enzymes

Pathway and Disease: Lipid Metabolism, Carbohydrate Metabolism

Description:
Aldo-keto reductase family 1 member C3 (AKR1C3) catalyzes the conversion of aldehydes and ketones to alcohols. AKR1C3 catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. AKR1C3 functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. AKR1C3 can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. AKR1C3 preferentially transforms androstenedione (4-dione) to testosterone. AKR1C3 is strongly inhibited by nonsteroidal anti-inflammatory drugs (NSAID) including flufenamic acid and indomethacin. AKR1C3 is also inhibited by the flavinoid rutin, and by selective serotonin inhibitors (SSRIs).

Alternate Names: Aldo-keto reductase family 1 member C3, Trans-1, 2-dihydrobenzene-1, 2-diol dehydrogenase, 3-alpha-hydroxysteroid dehydrogenase type 2, 3-alpha-HSD type 2, 3-alpha-HSD type II, brain, Testosterone 17-beta-dehydrogenase 5, 17-beta-hydroxysteroid dehydrogenase type 5, 17-beta-HSD 5, Prostaglandin F synthase, PGFS, Indanol dehydrogenase, Dihydrodiol dehydrogenase type I, Dihydrodiol dehydrogenase 3, DD-3, DD3, Chlordecone reductase homolog HAKRb, HA1753, AKR1C3, DDH1, HSD17B5, KIA0119, PGFS

Application Notes: E: 1:10,000-1:30,000; WB: 1:100-1:1,000; IF: 1:50-1:200; IHC: 1:100-1:500

Accession No.: P42330

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human AKR1C3.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4, 2% BSA with 0.02% sodium azide. Antibody was purified by antigen-affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.